| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2015 | COLL Collegium Pharmaceutical, Inc | Longitude Capital Partners, LLC | 10% Owner | Buy | 200,000 | $12.00 | $2,400,000.00 | +6.4% | |
| May 11, 2015 | TXMD Therapeuticsmd, Inc. | Thompson Tommy G51 | Director, Chairman | Buy | 6,000 | $6.09 | $36,540.00 | +0.9% | |
| May 11, 2015 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 10,634 | $60.44 | $642,767.88 | -100% | |
| May 8, 2015 | MRK Merck & Co., Inc. | Gerberding Julie L. | EVP Strat Comm, Gl Pub Policy | Sell | 38,368 | $60.99 | $2,339,949.22 | -54.5% | |
| May 8, 2015 | TXMD Therapeuticsmd, Inc. | Carroll J Martin53 | Director | Buy | 10,000 | $6.11 | $61,100.00 | New | |
| May 8, 2015 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 195,000 | $73.28 | $14,289,795.00 | -0.1% | |
| May 7, 2015 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 40,000 | $3.13 | $125,116.00 | +66.7% | |
| May 4, 2015 | MRK Merck & Co., Inc. | Kuhlik Bruce N | Exe V-p &Gen Counsel | Sell | 56,064 | $60.20 | $3,374,794.91 | -27.2% | |
| May 1, 2015 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 200,000 | $73.09 | $14,617,600.00 | -0.2% | |
| Apr 29, 2015 | MRK Merck & Co., Inc. | Kuhlik Bruce N | Exe V-p &Gen Counsel | Sell | 156,902 | $59.82 | $9,386,645.77 | -29.2% | |
| Apr 29, 2015 | MRK Merck & Co., Inc. | Holston Michael J | EVP, Legal | Sell | 95,624 | $59.84 | $5,722,541.78 | -70.5% | |
| Apr 28, 2015 | JNJ Johnson & Johnson | Stoffels Paulus | Chief Scientific Officer | Sell | 187,250 | $100.73 | $18,862,141.90 | -66.5% | |
| Apr 27, 2015 | ELTP Elite Pharmaceuticals Inc /nv/ | Plassche Douglas | Executive VP Of Operations | Sell | 85,530 | $0.24 | $20,167.97 | -53.9% | |
| Apr 24, 2015 | ESPR Esperion Therapeutics, Inc. | Aisling Capital II LP | 10% Owner | Sell | 217,469 | $108.22 | $23,534,372.60 | -3.7% | |
| Apr 24, 2015 | ESPR Esperion Therapeutics, Inc. | Goldstein Dov A Md | Director | Sell | 217,469 | $108.22 | $23,534,372.60 | -3.7% | |
| Apr 22, 2015 | AKBA Akebia Therapeutics, Inc. | Satter Muneer A58 | Director | Buy | 420,000 | $8.25 | $3,465,000.00 | +26.5% | |
| Apr 15, 2015 | PCRX Pacira Biosciences, Inc. | Stack David M67 | President, CEO And Chairman | Sell | 25,000 | $90.50 | $2,262,475.00 | -99.8% | |
| Apr 10, 2015 | PCRX Pacira Biosciences, Inc. | Hastings Paul J75 | Director | Sell | 2,500 | $88.00 | $220,000.00 | -74.6% | |
| Apr 9, 2015 | AMPH Amphastar Pharmaceuticals, Inc. | Purchase Marilyn J. | Corp. Exec. VP Of Operations | Sell | 28,000 | $15.79 | $442,120.00 | -38.4% | |
| Apr 8, 2015 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | Corp. SVP Of Quality Assurance | Sell | 10,000 | $15.79 | $157,900.00 | -33.9% | |
| Apr 8, 2015 | LFCR Lifecore Biomedical, Inc. \de\ | Frank Fred | Director | Sell | 20,000 | $14.71 | $294,217.84 | -18.1% | |
| Apr 2, 2015 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,483 | $9.09 | $13,477.65 | -1.9% | |
| Apr 2, 2015 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 996 | $9.09 | $9,051.75 | -7.7% | |
| Mar 30, 2015 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $73.94 | $13,308,660.00 | -0.1% | |
| Mar 30, 2015 | SUPN Supernus Pharmaceuticals, Inc. | Bryan Jones W. | VP Of Business Development | Sell | 6,712 | $12.02 | $80,646.69 | -9.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.